9,180 Shares in Smith & Nephew SNATS, Inc. (NYSE:SNN) Acquired by Callan Capital LLC

Callan Capital LLC acquired a new position in Smith & Nephew SNATS, Inc. (NYSE:SNN - Free Report) during the 1st quarter, according to its most recent filing with the SEC. The fund acquired 9,180 shares of the medical equipment provider's stock, valued at approximately $260,000.

Several other institutional investors and hedge funds have also made changes to their positions in SNN. River Road Asset Management LLC raised its stake in Smith & Nephew SNATS by 64.0% in the 4th quarter. River Road Asset Management LLC now owns 2,032,016 shares of the medical equipment provider's stock valued at $49,947,000 after purchasing an additional 792,829 shares during the last quarter. J. Goldman & Co LP acquired a new position in Smith & Nephew SNATS in the 4th quarter valued at about $47,700,000. Brandes Investment Partners LP raised its stake in Smith & Nephew SNATS by 11.4% in the 4th quarter. Brandes Investment Partners LP now owns 1,363,039 shares of the medical equipment provider's stock valued at $33,504,000 after purchasing an additional 138,994 shares during the last quarter. Envestnet Asset Management Inc. raised its stake in Smith & Nephew SNATS by 15.6% in the 1st quarter. Envestnet Asset Management Inc. now owns 618,691 shares of the medical equipment provider's stock valued at $17,552,000 after purchasing an additional 83,341 shares during the last quarter. Finally, Northern Trust Corp raised its stake in Smith & Nephew SNATS by 169.9% in the 4th quarter. Northern Trust Corp now owns 508,392 shares of the medical equipment provider's stock valued at $12,496,000 after purchasing an additional 320,054 shares during the last quarter. 25.64% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. UBS Group downgraded shares of Smith & Nephew SNATS from a "buy" rating to a "neutral" rating in a research note on Wednesday, March 12th. HSBC lowered shares of Smith & Nephew SNATS from a "buy" rating to a "hold" rating in a report on Friday, April 25th. Hsbc Global Res lowered shares of Smith & Nephew SNATS from a "strong-buy" rating to a "hold" rating in a report on Friday, April 25th. Finally, Canaccord Genuity Group increased their price objective on shares of Smith & Nephew SNATS from $27.00 to $28.00 and gave the stock a "hold" rating in a report on Thursday, May 1st. Six research analysts have rated the stock with a hold rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $28.00.

Smith & Nephew SNATS Trading Up 1.2%

Shares of SNN stock traded up $0.36 during trading hours on Thursday, hitting $31.05. 2,866,754 shares of the company were exchanged, compared to its average volume of 821,921. The firm has a market cap of $13.60 billion, a PE ratio of 14.37, a PEG ratio of 0.94 and a beta of 0.69. Smith & Nephew SNATS, Inc. has a 1 year low of $23.69 and a 1 year high of $31.72. The company has a quick ratio of 1.33, a current ratio of 2.89 and a debt-to-equity ratio of 0.62. The firm has a fifty day moving average of $29.24 and a 200 day moving average of $27.37.

Smith & Nephew SNATS Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.